Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial by Leili Gao & Byung Wan Lee & Manoj Chawla & Joshua Kim & Li Huo & Liying Du & Yan Huang & Linong Ji

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial by Leili Gao & Byung Wan Lee & Manoj Chawla & Joshua Kim & Li Huo & Liying Du & Yan Huang & Linong Ji

Author:Leili Gao & Byung Wan Lee & Manoj Chawla & Joshua Kim & Li Huo & Liying Du & Yan Huang & Linong Ji
Format: pdf
Tags: Nature Medicine, doi:10.1038/s41591-023-02344-1
Publisher: Springer US
Published: 2023-06-21T11:13:02+00:00


Download



Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.